Today, the U.S. Food and Drug Administration approved Soma (carisprodol) for the first-line treatment of patients experiencing mild-to-moderate back pain. This marks the first muscle relaxant therapy approved for this patient population as a first-line daily treatment.
The FDA’s approval for this indication was based on the results of one multicenter, international, open-label, active-controlled, randomized trial that showed promising results.